NasdaqCM - Nasdaq Real Time Price USD

Cue Biopharma, Inc. (CUE)

0.6020

-0.0337

(-5.30%)

At close: June 13 at 4:00:02 PM EDT

0.6100

+0.01

+(1.33%)

After hours: June 13 at 6:26:52 PM EDT

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of -21.43% and 78.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

CUE
-5.30%
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise Successfully regained worldwide rights for lead autoimmune program, CUE-401, with potential to become a new standard of care for autoimmune and inflammatory diseases Virtual Event planned for May 15, 2025 at 11 AM ET, featuring two prominent Key Opini

GlobeNewswire last month

CUE
-5.30%
Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual inv

GlobeNewswire last month

CUE
-5.30%
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025. During the fireside chat, Cue Biopharma will discuss progress on its programs f

GlobeNewswire last month

CUE
-5.30%
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

CUE
-5.30%
Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

CUE
-5.30%

HRMY
Boehringer, Oxford University and Cumulus to explore brain activity in BPD

The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population.

Pharmaceutical Technology last month

CUE
-5.30%
Boehringer and Cue Biopharma to develop autoimmune therapies

Cue will receive a $12m upfront payment from Boehringer, along with research support.

Pharmaceutical Technology last month

CUE
-5.30%
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii)

GlobeNewswire last month

CUE
-5.30%
Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of com

GlobeNewswire last month

CUE
-5.30%
Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1

GlobeNewswire last month

CUE
-5.30%
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease

GlobeNewswire last month

CUE
-5.30%
Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cue Biopharma ( NASDAQ:CUE ) Full Year 2024 Results Key Financial Results Revenue: US$9.29m (up 69% from FY 2023). Net...

Simply Wall St. 2 months ago

CUE
-5.30%
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CUE
-5.30%
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results. Prioritized resources on potentially disruptive autoimmune programs while enabling maturation of clinical data from oncology programs to further su

GlobeNewswire 2 months ago

CUE
-5.30%
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 2 months ago

TGTX

CUE
-5.30%
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Compa

GlobeNewswire 6 months ago

CUE
-5.30%
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024. During the fireside discussion, Cue Biopharma

GlobeNewswire 6 months ago

CUE
-5.30%
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations

Cue Biopharma ( NASDAQ:CUE ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.34m (up 59% from 3Q 2023...

Simply Wall St. 6 months ago

CUE
-5.30%
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

CUE
-5.30%

Performance Overview

Return	CUE	S&P 500 (^GSPC)
YTD	-44.77%	+1.62%
1-Year	-60.91%	+10.00%
3-Year	-80.89%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Boehringer, Oxford University and Cumulus to explore brain activity in BPD

Boehringer and Cue Biopharma to develop autoimmune therapies

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

Performance Overview